Literature DB >> 20347017

Evaluation of Krebs cycle enzymes in the brain of rats after chronic administration of antidepressants.

Giselli Scaini1, Patricia M Santos, Joana Benedet, Natália Rochi, Lara M Gomes, Lislaine S Borges, Gislaine T Rezin, Daiana P Pezente, João Quevedo, Emilio L Streck.   

Abstract

Several works report brain impairment of metabolism as a mechanism underlying depression. Citrate synthase and succinate dehydrogenase are enzymes localized within cells in the mitochondrial matrix and are important steps of Krebs cycle. In addition, citrate synthase has been used as a quantitative enzyme marker for the presence of intact mitochondria. Thus, we investigated citrate synthase and succinate dehydrogenase activities from rat brain after chronic administration of paroxetine, nortriptiline and venlafaxine. Adult male Wistar rats received daily injections of paroxetine (10mg/kg), nortriptiline (15mg/kg), venlafaxine (10mg/kg) or saline in 1.0mL/kg volume for 15 days. Twelve hours after the last administration, the rats were killed by decapitation, the hippocampus, striatum and prefrontal cortex were immediately removed, and activities of citrate synthase and succinate dehydrogenase were measured. We verified that chronic administration of paroxetine increased citrate synthase activity in the prefrontal cortex, hippocampus, striatum and cerebral cortex of adult rats; cerebellum was not affected. Chronic administration of nortriptiline and venlafaxine did not affect the enzyme activity in these brain areas. Succinate dehydrogenase activity was increased by chronic administration of paroxetine and nortriptiline in the prefrontal cortex, hippocampus, striatum and cerebral cortex of adult rats; cerebellum was not affected either. Chronic administration of venlafaxine increased succinate dehydrogenase activity in prefrontal cortex, but did not affect the enzyme activity in cerebellum, hippocampus, striatum and cerebral cortex. Considering that metabolism impairment is probably involved in the pathophysiology of depressive disorders, an increase in these enzymes by antidepressants may be an important mechanism of action of these drugs. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347017     DOI: 10.1016/j.brainresbull.2010.03.006

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  14 in total

1.  Altered Monoamine and Acylcarnitine Metabolites in HIV-Positive and HIV-Negative Subjects With Depression.

Authors:  Edana Cassol; Vikas Misra; Susan Morgello; Gregory D Kirk; Shruti H Mehta; Dana Gabuzda
Journal:  J Acquir Immune Defic Syndr       Date:  2015-05-01       Impact factor: 3.731

2.  Minocycline protects against oxidative damage and alters energy metabolism parameters in the brain of rats subjected to chronic mild stress.

Authors:  Gislaine Z Réus; Helena M Abelaira; Amanda L Maciel; Maria Augusta B Dos Santos; Anelise S Carlessi; Amanda V Steckert; Gabriela K Ferreira; Samira D De Prá; Emilio L Streck; Danielle S Macêdo; João Quevedo
Journal:  Metab Brain Dis       Date:  2014-08-13       Impact factor: 3.584

3.  Dysregulation of mitochondrial dynamics, mitophagy and apoptosis in major depressive disorder: Does inflammation play a role?

Authors:  Giselli Scaini; Brittany L Mason; Alexandre P Diaz; Manish K Jha; Jair C Soares; Madhukar H Trivedi; João Quevedo
Journal:  Mol Psychiatry       Date:  2021-10-14       Impact factor: 15.992

4.  Treatment with tianeptine induces antidepressive-like effects and alters the neurotrophin levels, mitochondrial respiratory chain and cycle Krebs enzymes in the brain of maternally deprived adult rats.

Authors:  Franciela P Della; Helena M Abelaira; Gislaine Z Réus; Maria Augusta B dos Santos; Débora B Tomaz; Altamir R Antunes; Giselli Scaini; Meline O S Morais; Emilio L Streck; João Quevedo
Journal:  Metab Brain Dis       Date:  2013-01-18       Impact factor: 3.584

5.  Altered functional protein networks in the prefrontal cortex and amygdala of victims of suicide.

Authors:  Katalin Adrienna Kékesi; Gábor Juhász; Attila Simor; Péter Gulyássy; Eva Mónika Szegő; Eva Hunyadi-Gulyás; Zsuzsanna Darula; Katalin F Medzihradszky; Miklós Palkovits; Botond Penke; András Czurkó
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240

6.  Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates.

Authors:  K Weckmann; C Labermaier; J M Asara; M B Müller; C W Turck
Journal:  Transl Psychiatry       Date:  2014-11-11       Impact factor: 6.222

7.  Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo.

Authors:  R Kaddurah-Daouk; M B Bogdanov; W R Wikoff; H Zhu; S H Boyle; E Churchill; Z Wang; A J Rush; R R Krishnan; E Pickering; M Delnomdedieu; O Fiehn
Journal:  Transl Psychiatry       Date:  2013-01-22       Impact factor: 6.222

8.  Metabolite profiling of antidepressant drug action reveals novel drug targets beyond monoamine elevation.

Authors:  C Webhofer; P Gormanns; V Tolstikov; W Zieglgänsberger; I Sillaber; F Holsboer; C W Turck
Journal:  Transl Psychiatry       Date:  2011-12-13       Impact factor: 6.222

9.  The effect of chronic tianeptine administration on the brain mitochondria: direct links with an animal model of depression.

Authors:  Katarzyna Głombik; Aneta Stachowicz; Rafał Olszanecki; Joanna Ślusarczyk; Ewa Trojan; Władysław Lasoń; Marta Kubera; Bogusława Budziszewska; Michael Spedding; Agnieszka Basta-Kaim
Journal:  Mol Neurobiol       Date:  2016-03-02       Impact factor: 5.590

10.  Ketamine's antidepressant effect is mediated by energy metabolism and antioxidant defense system.

Authors:  Katja Weckmann; Michael J Deery; Julie A Howard; Renata Feret; John M Asara; Frederik Dethloff; Michaela D Filiou; Jamie Iannace; Christiana Labermaier; Giuseppina Maccarrone; Christian Webhofer; Larysa Teplytska; Kathryn Lilley; Marianne B Müller; Christoph W Turck
Journal:  Sci Rep       Date:  2017-11-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.